Renin-angiotensin-aldosterone system (RAAS) dependent hypertension, diabetes featured by hyperglycemia, hyperlipidemia, hyperuricemia, hyperhomocysteinemia, overweight or obesity etc., represent the major types of endocrine and metabolic disorders which contribute most to the development of atherosclerosis-based cardiovascular diseases. In clinical studies, these diseases comprise nonfatal myocardial infarction, nonfatal cerebral infarction, or even cardiovascular death, termed 3 major adverse cardiovascular events (3p MACE). On one side, these endocrine or metabolic dysfunctions are the upstream risk factors of cardiovascular diseases. Meanwhile, more and more antidiabetic drugs, e.g., glucagon-like peptide-1 (GLP-1) receptor agonists, sodium-glucose transporter-2 inhibitors (SGLT2i) etc., are reported to have not only blood glucose lowering effects, but also have direct cardiovascular protective effects independent of the glucose lowering effects. Regarding the close relationship between endocrine or metabolic disorders and downstream cardiovascular outcomes, a call for a new subspeciality in internal medicine, cardiometabolic medicine, was proposed in Am J Med, 2019.
Recently, many basic or clinical studies focused on endocrine and metabolic cardiovascular outcomes. The goal of this Research Topic is to compile recent advances concentrating in this area, both in terms of basic and clinical aspects, to further value the cardiovascular outcomes in treating endocrine and metabolic diseases.
Submission of original articles, reviews, mini reviews, and commentaries are welcomed. Topics of interest include but are not limited to:
• Molecular mechanisms, key signaling pathways and novel therapeutic strategies in the endocrine or metabolic cardiovascular diseases.
• Novel mechanism of action of glucagon like peptide-1(GLP-1) receptor agonists, sodium-Glucose transporter-2 inhibitors (SGLT2i) or other therapies in the treatment of endocrine or metabolic cardiovascular diseases.
• Clinical trials concerning endocrine and metabolic cardiovascular outcomes.
Renin-angiotensin-aldosterone system (RAAS) dependent hypertension, diabetes featured by hyperglycemia, hyperlipidemia, hyperuricemia, hyperhomocysteinemia, overweight or obesity etc., represent the major types of endocrine and metabolic disorders which contribute most to the development of atherosclerosis-based cardiovascular diseases. In clinical studies, these diseases comprise nonfatal myocardial infarction, nonfatal cerebral infarction, or even cardiovascular death, termed 3 major adverse cardiovascular events (3p MACE). On one side, these endocrine or metabolic dysfunctions are the upstream risk factors of cardiovascular diseases. Meanwhile, more and more antidiabetic drugs, e.g., glucagon-like peptide-1 (GLP-1) receptor agonists, sodium-glucose transporter-2 inhibitors (SGLT2i) etc., are reported to have not only blood glucose lowering effects, but also have direct cardiovascular protective effects independent of the glucose lowering effects. Regarding the close relationship between endocrine or metabolic disorders and downstream cardiovascular outcomes, a call for a new subspeciality in internal medicine, cardiometabolic medicine, was proposed in Am J Med, 2019.
Recently, many basic or clinical studies focused on endocrine and metabolic cardiovascular outcomes. The goal of this Research Topic is to compile recent advances concentrating in this area, both in terms of basic and clinical aspects, to further value the cardiovascular outcomes in treating endocrine and metabolic diseases.
Submission of original articles, reviews, mini reviews, and commentaries are welcomed. Topics of interest include but are not limited to:
• Molecular mechanisms, key signaling pathways and novel therapeutic strategies in the endocrine or metabolic cardiovascular diseases.
• Novel mechanism of action of glucagon like peptide-1(GLP-1) receptor agonists, sodium-Glucose transporter-2 inhibitors (SGLT2i) or other therapies in the treatment of endocrine or metabolic cardiovascular diseases.
• Clinical trials concerning endocrine and metabolic cardiovascular outcomes.
